- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00617032
Phase 1 Dose Escalation Study of Intra-Articular Administration of tgAAC94
A Phase 1 Dose Escalation Study of Intra-Articular Administration of tgAAC94, a Recombinant Adeno-Associated Vector Containing the TNFR:Fc Fusion Gene, in Inflammatory Arthritis
Study 1304 is a Phase I dose escalation study conducted in adults with persistent moderate (grade 2) or severe (grade 3) swelling due to inflammatory arthritis (rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis) in at least one peripheral joint eligible for injection. Disease must not be severe enough to warrant use of a TNF-alpha antagonist in the next three months.
Current use of TNF-alpha antagonists is not permitted. Subjects with rheumatoid arthritis must have had an adequate trial of at least one disease-modifying antirheumatic drug (DMARD) prior to screening.
The primary objective is to evaluate the safety of intra-articular administration of tgAAC94.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
tgAAC94 is a recombinant adeno-associated virus serotype 2 (AAV2) vector genetically engineered to contain the cDNA for a human tumor necrosis factor receptor (TNFR)-immunoglobulin (IgG1) Fc fusion (TNFR:Fc) gene. The DNA sequence of TNFR:Fc in tgAAC94 codes for a protein sequence identical to etanercept (Enbrel). TNF-alpha has been strongly implicated as a major participant in the inflammatory cascade that leads to joint damage and destruction in diseases such as rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS).
Intra-articular delivery of the TNFR:Fc gene (tgAAC94) should result in expression of the secreted protein in the joint space and provide local high concentrations of soluble TNFR:Fc for an extended period of time without requiring frequent administration. Thus, this proposed therapy would be useful in those inflammatory arthritis patients who have a persistently problematic joint despite the use of systemic TNF-alpha blockade or who have a limited number of arthritic joints.
Extensive preclinical studies using rAAV2 containing several different transgenes in a variety of animal models have shown efficient and persistent gene transfer and expression with minimal toxicity. The parent virus (wild-type AAV2) is a naturally occurring, non-replicating virus that depends on a helper virus, such as adenovirus, for replication. The recombinant AAV2 vector is unable to replicate in target host cells because it lacks the AAV genes, whose protein products are also required in trans, for replication and packaging of progeny virus. Extensive epidemiological studies have found AAV2 to be non-pathogenic.
Although there is no cure for inflammatory arthritis, treatment has been revolutionized by the advent of anti-TNF-alpha therapies. These include etanercept (Enbrel), infliximab (Remicade) and adalimumab (Humira), which consist of soluble TNF receptors, chimeric human-mouse anti-TNF-alpha monoclonal antibodies and fully human anti-TNF-alpha monoclonal antibodies, respectively. Clinical studies have shown these products to improve the signs and symptoms, inhibit the structural damage, and impact functional outcomes in patients with inflammatory arthritis.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
British Columbia
-
Vancouver, British Columbia, Canada
- Arthritis Research Centre of Canada
-
-
Manitoba
-
Winnipeg, Manitoba, Canada
- Arthritis Centre Clinical Research Unit UofManitoba
-
-
Ontario
-
Toronto, Ontario, Canada
- Toronto Western Hospital
-
Toronto, Ontario, Canada
- Mt Sinai Hospital
-
-
-
-
California
-
Los Angeles, California, United States
- UCLA Division of Rheumatology
-
-
Colorado
-
Denver, Colorado, United States
- Denver Arthritis Research Center
-
-
Washington
-
Seattle, Washington, United States
- Swedish Rheumoatology Research
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis, diagnosed according to published criteria
- Persistent moderate (grade 2) or sever (grade 3) swelling due to inflammatory arthritis in at least one peripheral joint eligible for injection
- For subjects with rheumatoid arthritis, an adequate trial of at least one disease-modifying antirheumatic drug (DMARD) prior to screening
- For subjects currently on DMARD(s), a stable regimen for inflammatory arthritis for the previous three months, with no changes in doses in the four weeks prior to screening
- Age greater than 18 years
- Be willing to practice effective birth control measures during the study, if of reproductive ability
- Able to give written informed consent
Exclusion Criteria:
- Current use of a TNF-alpha antagonist
- Disease severe enough to warrant use of a systemic TNF-alpha antagonist in the next three months
- Discontinuation of TNF-alpha antagonists in the past because of safety concerns
- Current use of anakinra
- Poor functional status, defined as being bed-bound or wheelchair-bound
- Corticosteriod therapy at doses higher than the equivalent of 10 mg prednisone per day
- Any of the following laboratory values: Hemoglobin <8.5 gm/dL, white blood cell count <3500 per mm^3, platelet <100 K/microL, creatinine >2 mg/dL, bilirubin >2 mg/dL, AST or ALT >2 times the upper limit of normal, or abnormal coagulation profiles
- Known HIV infection, known hepatitis C infection, or known positive serologic test for hepatitis B surface antigen
- Positive PPD, unless previously treated with appropriate prophylaxis
- Pregnancy or lactation, either at the time of screening or planned in the next six months
- Inflammatory bowel disease, such as Crohn's disease or ulcerative colitis
- Serious medical disease, such as sever liver or kidney disease, uncompensated congestive heart failure, myocardial infarction within six months, unstable angina, uncontrolled hypertension, severe pulmonary disease or active asthma, demyelinating neurological disease, history of cancer (other than cutaneous basal and squamous cell carcinoma) with less than five years documentation of a disease free state, insulin-dependent diabetes, recurrent opportunistic infections or other concurrent medical condition that, in the opinion of the investigator, would make the subject unsuitable for the study
- Unlikely to comply with the protocol
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: 1
1x10^10 DRP/mL tgAAC94
|
Single Dose 1x10^10 DNase resistant particles (DRP) / mL joint volume
Single dose 1x10^11 DNase resistant particles (DRP) / mL joint volume
|
ACTIVE_COMPARATOR: 2
1x10^11 DRP/mL tgAAC94
|
Single Dose 1x10^10 DNase resistant particles (DRP) / mL joint volume
Single dose 1x10^11 DNase resistant particles (DRP) / mL joint volume
|
PLACEBO_COMPARATOR: 3
Single dose tgAAC94 placebo
|
Single dose
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Serious adverse events
Time Frame: From study drug administration through final study visit
|
From study drug administration through final study visit
|
Severe or very severe adverse events
Time Frame: From study drug administration through final study visit
|
From study drug administration through final study visit
|
Study drug-related adverse events
Time Frame: From study drug administration through final study visit
|
From study drug administration through final study visit
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in tenderness and swelling of injected joint
Time Frame: Days 3 and 7 and Weeks 2, 4, 8, and 12
|
Days 3 and 7 and Weeks 2, 4, 8, and 12
|
Change in tenderness and swelling of non-injected joints
Time Frame: Weeks 2, 4, and 12
|
Weeks 2, 4, and 12
|
Reduction in disease activity, as measured by American College of Rheumatology (ACR) criteria and Disease Activity Score (DAS)
Time Frame: Weeks 2, 4, and 12
|
Weeks 2, 4, and 12
|
Joint fluid measures (cell count and differential, total protein and TNFR:Fc protein)
Time Frame: Weeks 4 and 12
|
Weeks 4 and 12
|
TNFR:Fc protein levels in serum
Time Frame: Day 7 and Weeks 2, 4, 8, and 12
|
Day 7 and Weeks 2, 4, 8, and 12
|
Serum neutralizing antibodies to AAV2
Time Frame: Weeks 4 and 12
|
Weeks 4 and 12
|
Presence of tgAAC94 in peripheral blood mononuclear cells (PBMCs)
Time Frame: Day 3 and Weeks 2 and 8
|
Day 3 and Weeks 2 and 8
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Alison Heald, MD, Targeted Genetics Corporation
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 13E04
- RAC Protocol # 0307-588
- HPB 0088676
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Rheumatoid Arthritis
-
Janssen Research & Development, LLCWithdrawnActive Rheumatoid Arthritis; Rheumatoid Arthritis
-
Centocor, Inc.CompletedRheumatoid Arthritis, Juvenile
-
AmgenTerminated
-
Children's Hospital Medical Center, CincinnatiNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)CompletedJuvenile Rheumatoid ArthritisUnited States
-
AmgenImmunex CorporationCompletedJuvenile Rheumatoid Arthritis
-
National Institute of Arthritis and Musculoskeletal...Children's Hospital Medical Center, CincinnatiCompleted
-
University of PittsburghNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)CompletedRheumatoid Arthritis | Juvenile Rheumatoid ArthritisUnited States
-
University of Missouri-ColumbiaCompletedJuvenile Rheumatoid ArthritisUnited States
-
Assistance Publique - Hôpitaux de ParisSociete Francaise de RhumatologieRecruiting
-
Amsterdam UMC, location VUmcEuropean CommissionCompletedRheumatoId ArthritisNetherlands, Germany, Portugal, Italy, Hungary, Romania, Slovakia
Clinical Trials on tgAAC94 gene therapy vector
-
Targeted Genetics CorporationCompletedArthritis, Rheumatoid | Arthritis, Psoriatic | Ankylosing SpondylitisUnited States
-
Children's Hospital of Chongqing Medical UniversityRecruiting
-
University of California, Los AngelesNational Heart, Lung, and Blood Institute (NHLBI); Boston Children's Hospital; California Institute for Regenerative Medicine (CIRM) and other collaboratorsRecruitingGranulomatous Disease, Chronic, X-linkedUnited States
-
GenethonCompletedLimb Girdle Muscular Dystrophy Type 2C | Gamma-sarcoglycanopathyFrance
-
Spark TherapeuticsActive, not recruitingConfirmed Biallelic RPE65 Mutation-associated Retinal DystrophyUnited States
-
Spark Therapeutics, Inc.Children's Hospital of Philadelphia; University of IowaActive, not recruitingLeber Congenital Amaurosis | Inherited Retinal Dystrophy Due to RPE65 MutationsUnited States
-
St. Jude Children's Research HospitalChildren's Hospital of Philadelphia; National Heart, Lung, and Blood Institute... and other collaboratorsActive, not recruitingHemophilia BUnited States, United Kingdom
-
National Taiwan University HospitalPTC TherapeuticsCompletedAromatic L-amino Acid Decarboxylase (AADC) DeficiencyTaiwan
-
University of Massachusetts, WorcesterNational Heart, Lung, and Blood Institute (NHLBI); University of Florida; National... and other collaboratorsCompletedAlpha 1-Antitrypsin DeficiencyUnited States
-
Tocagen Inc.CompletedGlioblastoma | Anaplastic Oligoastrocytoma | Anaplastic Astrocytoma | Anaplastic OligodendrogliomaUnited States